Trial · NCT02342704
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cumulative Number of ≥ 6-Month Confirmed T1-Hypointense Lesions Arising From New On-Treatment T1-Gadolinium-Enhancing (Gd+) Lesions | Up to Week 52 | The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis. | ||
| SECONDARY | Cumulative Number of New T1-Gd+ Lesions | Baseline, Week 4, Week 12, Week 24 | Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment. | lesions | MEAN |
| SECONDARY | Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 24 | Baseline, Week 24 | Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had an assessment. | percentage change | MEAN |
| SECONDARY | Change From Baseline in Total T1-Hypointense and Total T2-Hyperintense Lesion Volumes at Week 52 | Baseline, Week 52 | Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had an assessment. | percentage change | MEAN |
| SECONDARY | Cumulative Number of New or Enlarging T2 Lesions | Baseline, Week 24 | Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had an assessment. | lesions | MEAN |
| SECONDARY | Proportion of Participants With No Evidence of Disease Activity (NEDA) | Up to Week 52 | The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis. | ||
| SECONDARY | Time to First Relapse | Up to Week 52 | The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis. | ||
| SECONDARY | Cumulative Risk of Relapse | Up to Week 52 | The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis. | ||
| SECONDARY | Time to Complete Recovery From First Relapse | Up to Week 52 | The limited number of participants enrolled and the early termination of the study resulted in efficacy data not collected, and efficacy outcomes not analyzed, as per the pre-specified plan of analysis. | ||
| SECONDARY | Change From Baseline in Symbol Digit Modalities Test (SDMT) at Week 24 | Baseline, Week 24 | Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had both baseline and post-baseline values. | units on a scale | MEAN |
| SECONDARY | Change From Baseline in SDMT at Week 52 | Baseline, Week 52 | Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment and had both baseline and post-baseline values. | units on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02342704/outcomes